BRAF/MEK combo raises risk of cardiovascular adverse events compared to BRAF monotherapy only
Three BRAF inhibitors -- dabrafenib, vemurafenib, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
Three BRAF inhibitors -- dabrafenib, vemurafenib, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
